-
公开(公告)号：KR100591238B1
公开(公告)日：2006-06-19
申请号：KR1020030061321
申请日：2003-09-03
Applicant: 권호정 , 다카라코리아바이오메디칼(주)
IPC: C12N9/16
Abstract: 본 발명은 신규한 내열성 히스톤 탈아세틸화 효소 및 그를 인코딩하는 신규한 뉴클레오타이드 서열을 포함하는 핵산 분자에 관한 것이다. 또한, 본 발명은 히스톤 탈아세틸화 효소를 인코딩하는 신규한 뉴클레오타이드 서열을 포함하는 벡터 및 그를 포함하는 형질전환체에 관한 것이다. 본 발명의 히스톤 탈아세틸화 효소는 일반적인 효소에 있어서는 극한적인 환경인 고온 환경에서 최대의 활성을 나타내며, 이러한 특성은 광범위한 응용성을 제공한다.
히스톤 탈아세틸화 효소, 내열성, 서머스 칼도필러스-
公开(公告)号：KR1020030077496A
公开(公告)日：2003-10-01
申请号：KR1020030059285
申请日：2003-08-26
Applicant: 권호정
IPC: C07C251/54
Abstract: PURPOSE: Provided is demethoxycurcumin oxime having an activity inhibiting the generation of new blood vessels, which can be used for anticancer functional materials, especially beverages. CONSTITUTION: The demethoxycurcumin oxime represented by the formula 3 is synthesized by reacting demethoxycurcumin represented by the formula 1 with methyl iodide and K2CO3 in acetone. And the anticancer functional materials contain the demethoxycurcumin oxime and the beverage as the anticancer functional material additionally contains Bifidobacteria or Lactobacillus.
Abstract translation: 目的：提供具有抑制新血管生成的活性的脱甲氧基姜黄素肟，其可用于抗癌功能材料，特别是饮料。 构成：由式3表示的脱甲氧基姜黄素肟通过将由式1表示的脱甲氧基姜黄素与甲基碘和K 2 CO 3在丙酮中反应合成。 抗癌功能材料含有脱甲氧基姜黄素肟，作为抗癌功能材料的饮料还含有双歧杆菌或乳杆菌。
-
公开(公告)号：KR1020010109831A
公开(公告)日：2001-12-12
申请号：KR1020000030484
申请日：2000-06-02
Applicant: 권호정 , 서울기능식품 주식회사 , 주식회사 비피도
IPC: C12N1/20
Abstract: 본 발명은 올레아미드를 생산하는 토양에서 분리된 신균주
Streptomyces sp. KK90378 (KCTC18014P)와 이 균주에 의해 올레아미드를 생산하는 방법에 관한 것이다. 본 발명에 따른 신균주는 올레아미드의 생산능이 높기 때문에, 이 균주를 배양하여 수면을 유도하는 생리활성 물질인 올레아미드를 생산하거나 균체를 담체에 고정하여 배양함으로써 수면을 유도하는 생리활성 물질인 올레아미드를 효율적으로 생산할 수 있다.-
公开(公告)号：KR1020010109830A
公开(公告)日：2001-12-12
申请号：KR1020000030483
申请日：2000-06-02
IPC: C12P33/00
Abstract: 본 발명은 베타-사이크로덱스트린(β-시클로덱스트린: β-CD)에 포집된 콜레스테롤을 회수하기 위하여 CDase 효소생산 신균주
Bacillus sp. KCTC 18013p를 자연계로 부터 분리하였고 본균주를 사용하여 제조된 고정화 β-CD 가수분해 효소를 사용하여 β-CD를 분해하여 포집된 콜레스테롤을 유리시킴으로써 고수율로 콜레스테롤 및 β-CD에 포집된 저분자 화합물을 회수하는 방법에 관한 것이다.-
15.发明授权
公开(公告)号：KR100510874B1
公开(公告)日：2005-08-26
申请号：KR1020030018568
申请日：2003-03-25
Applicant: 권호정
IPC: A61K31/353 , A61P35/00
Abstract: 본 발명은 약제학적 유효량의 하기 화학식 1로 표시되는 호모이소플라바논 유도체를 유효성분으로 포함하는 비조절된 혈관신생-관련 질환의 치료 또는 예방용 약제학적 조성물에 관한 것이다.
화학식 1
상기 화학식에서 R
1 , R
2 및 R
3 는 각각 독립적으로 H, 직쇄 또는 분쇄 알킬기, 직쇄 또는 분쇄 알케닐기, 직쇄 또는 분쇄 알키닐기, 시클로 알킬기, 시클로 알케닐기, 아릴기, 알카릴기 또는 아랄킬기이다.-
Patent Agency Ranking
公开(公告)号：KR1020050024531A
公开(公告)日：2005-03-10
申请号：KR1020030061321
申请日：2003-09-03
Applicant: 권호정 , 다카라코리아바이오메디칼(주)
IPC: C12N9/16
CPC classification number: C12N9/80 , C12Q1/34 , C12Y305/01098
Abstract: PURPOSE: A thermophilic histone deacetylase and use thereof are provided, which enzyme has the optimal activity at high temperature that would be the severe environment for normal enzymes, so that the enzyme can be used in a wide range of applications. CONSTITUTION: The thermophilic histone deacetylase having the amino acid sequence set forth in SEQ ID NO:2 is provided, wherein the thermophilic histone deacetylase has properties of (a) isolation from Thermus caldophilus; (b) molecular weight of 38 to 42 kDa; (c) optimal temperature of 40 to 60 deg. C; and (d) optimal pH of 6.5 to 8.0. A nucleic acid molecule comprising the nucleotide sequence encoding the thermophilic histone deacetylase set forth in SEQ ID NO:1 is provided. A vector containing the nucleic acid molecule of SEQ ID NO:1 and a promoter operably linked to the nucleic acid molecule is provided. A transformant is produced by transforming a host cell with the vector containing the nucleic acid molecule of SEQ ID NO:1. A method for screening inhibitors of the thermophilic histone deacetylase comprises the steps of: (a) contacting a test sample with the thermophilic histone deacetylase; and (b) measuring the activity of the thermophilic histone deacetylase.
Abstract translation: 目的：提供嗜热组蛋白脱乙酰酶及其用途，该酶在高温下具有最佳的活性，这是正常酶的恶劣环境，因此该酶可用于广泛的应用。 构成：提供具有SEQ ID NO：2所示氨基酸序列的嗜热组蛋白脱乙酰酶，其中嗜热组蛋白脱乙酰酶具有以下特性：（a）与嗜热栖热菌分离; （b）分子量为38至42kDa; （c）最佳温度为40〜60℃。 C; 和（d）6.5至8.0的最佳pH。 提供了包含编码SEQ ID NO：1所示的嗜热组蛋白脱乙酰酶的核苷酸序列的核酸分子。 提供了含有SEQ ID NO：1的核酸分子的载体和与核酸分子可操作地连接的启动子。 通过用含有SEQ ID NO：1的核酸分子的载体转化宿主细胞产生转化体。 筛选嗜热组蛋白脱乙酰酶抑制剂的方法包括以下步骤：（a）使测试样品与嗜热组蛋白脱乙酰酶接触; 和（b）测量嗜热组蛋白脱乙酰酶的活性。
-
17.发明公开호모이소플라바논 유도체를 포함하는 비조절된혈관신생-관련 질환의 치료 및 예방용 약제학적 조성물 失效用于治疗或预防不连续的血管生成相关疾病的药物组合物，其包含作为活性成分的药物有效量的HOMOISOFLAVANONE衍生物
公开(公告)号：KR1020040083880A
公开(公告)日：2004-10-06
申请号：KR1020030018568
申请日：2003-03-25
Applicant: 권호정
IPC: A61K31/353 , A61P35/00
CPC classification number: A61K31/353 , A61K36/898 , A61K2236/333 , Y10S514/825
Abstract: PURPOSE: Provided is a pharmaceutical composition for treating or preventing uncontrolled angiogenesis-related diseases which comprises a pharmaceutically effective amount of homoisoflavanone derivatives as an active ingredient. CONSTITUTION: The pharmaceutical composition for treating or preventing uncontrolled angiogenesis-related diseases comprises a pharmaceutically effective amount of homoisoflavanone derivatives of the formula(1), as an active ingredient, and a pharmaceutically acceptable carrier. In the formula(1), R1, R2 and R3 are independently H, linear or branched alkenyl, linear or branched alkynyl, cyclo alkyl, cyclo alkenyl, aryl or aralalkyl.
Abstract translation: 目的：提供一种用于治疗或预防不受控制的血管发生相关疾病的药物组合物，其包含药学有效量的异丙基黄酮衍生物作为活性成分。 构成：用于治疗或预防不受控制的血管生成相关疾病的药物组合物包含药学有效量的作为活性成分的式（1）的高异黄酮酮衍生物和药学上可接受的载体。 在式（1）中，R 1，R 2和R 3独立地为H，直链或支链烯基，直链或支链炔基，环烷基，环烯基，芳基或芳烷基。
-
公开(公告)号：KR100416334B1
公开(公告)日：2004-01-31
申请号：KR1020030059287
申请日：2003-08-26
Applicant: 권호정
IPC: C07D231/12
Abstract: PURPOSE: A demethoxycurcumin derivative and an anti-cancer agent containing the same compound are provided, which compound has angiogenesis inhibiting activity, so that it can be used in functional anticancer agents, especially drink type of functional anticancer agents. CONSTITUTION: A hydrazine demethoxycurcumin derivative represented by formula 4 is provided. A method for preparing the hydrazine demethoxycurcumin of formula 4 comprises reacting demethoxycurcumin of formula 1 with methyliodide and K2CO3 in acetone. An anti-cancer agent for inhibiting angiogenesis contains hydrazine demethoxycurcumin of formula 4, wherein the anti-cancer agent is drink further comprising Bifidobacteria or Lactobacillus as lactic acid bacteria.
Abstract translation: 目的：提供了一种含有相同化合物的去甲氧基姜黄素衍生物和抗癌剂，该化合物具有血管生成抑制活性，因此可用于功能性抗癌剂，特别是饮用型功能性抗癌剂。 构成：提供由式4表示的肼去甲氧基姜黄素衍生物。 用于制备式4的肼去甲氧基姜黄素的方法包括使式1的去甲氧基姜黄素与甲基碘和K 2 CO 3在丙酮中反应。 用于抑制血管生成的抗癌剂包含式4的肼去甲氧基姜黄素，其中所述抗癌剂是进一步包含双歧杆菌或乳酸杆菌作为乳酸菌的饮料。
-
公开(公告)号：KR1020030075807A
公开(公告)日：2003-09-26
申请号：KR1020020015181
申请日：2002-03-20
Applicant: 권호정
IPC: C07C39/18
Abstract: PURPOSE: A novel bicyclic sesterterpene-based derivative and a pharmaceutical composition containing the derivative are provided, to obtain a pharmaceutical composition for treating or preventing the uncontrolled angiogenesis related disease. CONSTITUTION: The bicyclic sesterterpene-based derivative is represented by the formula 1, wherein R1, R2 and R3 are independently H, a linear or branched alkyl group, a linear or branched alkenyl group, a linear or branched alkynyl group, a cycloalkyl group, a cycloalkenyl group, an aryl group, an alkaryl group or an aralkyl group. Preferably R1, R2 and R3 are independently H or a methyl group in the formula 1. The pharmaceutical composition comprises the bicyclic sesterterpene-based derivative of the formula 1, and a pharmaceutically acceptable carrier.
Abstract translation: 目的：提供一种新型的双环西萜烯衍生物和含有该衍生物的药物组合物，以获得用于治疗或预防不受控制的血管生成相关疾病的药物组合物。 构成：双环辛萜基衍生物由式1表示，其中R 1，R 2和R 3独立地为H，直链或支链烷基，直链或支链烯基，直链或支链炔基，环烷基， 环烯基，芳基，烷芳基或芳烷基。 优选地，R 1，R 2和R 3独立地为H或式1中的甲基。药物组合物包含式1的双环西萜烯衍生物和药学上可接受的载体。
-
公开(公告)号：KR1020030074552A
公开(公告)日：2003-09-19
申请号：KR1020030059286
申请日：2003-08-26
Applicant: 권호정
IPC: C07C45/78
Abstract: PURPOSE: Provided is a method for extracting and purifying demethoxycurcumin from Curcuma aromatica which is a Chinese medicine material with a high efficiency. CONSTITUTION: The method for extracting demethoxycurcumin having angiogenesis inhibiting activity of the formula 1 from Curcuma aromatica comprises the step of heat treating Curcuma aromatica in methanol or ethanol extraction solvent at the temperature of 40 to 70 deg.C. In particular, the extraction solvent is methanol having a concentration of 60-100%, and the heat treating step is carried out for 1 to 10 hours.
Abstract translation: 目的：提供一种高效中药的姜黄素提取纯化脱甲氧基姜黄素的方法。 构成：从姜黄中提取具有式1的血管生成抑制活性的脱甲氧基姜黄素的方法包括在40〜70℃的温度下在甲醇或乙醇提取溶剂中热处理姜黄的步骤。 特别地，提取溶剂为浓度为60〜100％的甲醇，热处理工序进行1〜10小时。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.024 seconds)
